Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE…
IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical…
SCOTTSDALE, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical…
AUSTIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.…
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate…